CD40-CD40L and platelet function: Beyond hemostasis

Circulation Research

Volumn 92, Issue 9, 2003, Pages 944-946

  Freedman, Jane E ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD40 CD40L; Inflammation; Platelets; Thrombosis

Indexed keywords

BETA THROMBOGLOBULIN; CD40 ANTIGEN; CD40 LIGAND; FIBRINOGEN RECEPTOR ANTAGONIST; GUANINE NUCLEOTIDE BINDING PROTEIN; PADGEM PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; THROMBOCYTE FACTOR 4; TRANSFORMING GROWTH FACTOR BETA;

BLEEDING; BLOOD VESSEL OCCLUSION; CALCIUM TRANSPORT; CELL CULTURE; CIRCULATION; CYTOSKELETON; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MECHANISM; DRUG PROTEIN BINDING; EDITORIAL; ENDOTHELIUM CELL; HEART INFARCTION; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIGAND BINDING; MEGAKARYOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; ANTIGENS, CD40; BLOOD PLATELETS; CD40 LIGAND; INFLAMMATION; MODELS, BIOLOGICAL; PLATELET ACTIVATION; THROMBOSIS;

EID: 0038364055     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000074030.98009.FF     Document Type: Editorial

References (11)

1. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103:201-206.
2. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res. 1999;41:65-76.
3. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-1537.
4. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
5. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200-203.
6. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism. Nat Med. 2002;8:247-252.
7. Freedman JE. CD40 ligand-assessing risk instead of damage? N Engl J Med. 2003;348:1163-1165.
8. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, Simoons ML. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111.
9. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266-2268.
10. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003;92:1041-1048.
11. Peitsch MC, Jongeneel CV. A 3-D model for the CD40 ligand predicts that it is a compact trimer similar to the tumor necrosis factors. Int Immunol. 1993;5:233-238.